Thesis

196 Part II Chapter 8 Figure 4. Change in SerumBone Tumor Markers (BTMs) in the denosumab and non-denosumab group Figure 4. The BTMs ALP and P1NP (including the Upper limit of normal 98 IU/L for ALP and 59 ng/ mL for P1NP in [#] in men and premenopausal women and [*] 76 ng/mL for P1NP in postmenopausal patients) in the denosumab and non-denosumab group. Both BTMs decreased significantly in the denosumab and did not in the non-denosumab group.

RkJQdWJsaXNoZXIy MjY0ODMw